Researchers at the University of Pittsburgh and Carnegie Mellon University collaborated to create a customized app based on ...

Joannah Whitney uses a wheelchair for most of her day. On the river, she battles chop and wind and reminds herself that she's still capable of many things.

Almost 3 million people worldwide have multiple sclerosis. Muhammad Taimur Malik, MD, of St. Luke’s Neurology Associates ...

An international Phase 2 trial will test BMS-986368 as a potentially new oral therapy for managing multiple sclerosis-related ...

The first sign of multiple myeloma varies by person and may not occur until a later stage of the disease. Learn how to ...

In relapsing-remitting multiple sclerosis, activation of the peripheral immune system can lead to focal inflammation within the CNS. Over the past three decades, therapeutic development has been ...

Multiple sclerosis, the prototype of demyelinating disease in man, is a relapsing-remitting or progressively disabling disease of unknown cause. The first pathological descriptions of the disease ...

In part 2, Hans Lee, MD, shares practical tips for using linvoseltamab in heavily pretreated multiple myeloma and outlines trials that may expand its future role.

Researches at the University of Cincinnati's Gardner Neuroscience Institute could have discovered a new oral treatment that ...

Multiple myeloma (MM) remains a complex and heterogeneous hematologic malignancy with evolving therapeutic challenges. In recent years, immunotherapy has ...

Background Alexander disease is an autosomal dominant leukodystrophy caused by heterozygous pathogenic variants in the glial ...